New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus

Bouza, Emilio

doi:10.1111/j.1469-0691.2009.03091.x

Cited by 18 publications

(10 citation statements)

References 302 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A more recent example of an antibiotic associated with a potent antibiofilm effect is that of daptomycin. This bactericidal cyclic lipopeptide has an in vitro spectrum against Gram-positive pathogens through calcium-dependent disruption of membrane function, leading to potassium ion leakage and inhibition of DNA, RNA, and protein synthesis (224,225). In vitro studies suggested that daptomycin may quickly penetrate S. epidermidis biofilms, that it is effective against biofilms, and that it is bactericidal against stationary-phase and nondividing S. aureus (225)(226)(227)(228).…”

Section: Currently Used Approaches Do Not Specifically Target Biofilmmentioning

confidence: 99%

Biofilm-Related Infections: Bridging the Gap between Clinical Management and Fundamental Aspects of Recalcitrance toward Antibiotics

Lebeaux

Ghigo

Beloin

2014

Microbiol Mol Biol Rev

1,012

862

View full text Add to dashboard Cite

International audienceSurface-associated microbial communities, called biofilms, are present in all environments. Although biofilms play an important positive role in a variety of ecosystems, they also have many negative effects, including biofilm-related infections in medical settings. The ability of pathogenic biofilms to survive in the presence of high concentrations of antibiotics is called "recalcitrance" and is a characteristic property of the biofilm lifestyle, leading to treatment failure and infection recurrence. This review presents our current understanding of the molecular mechanisms of biofilm recalcitrance toward antibiotics and describes how recent progress has improved our capacity to design original and efficient strategies to prevent or eradicate biofilm-related infections

show abstract

Section: Currently Used Approaches Do Not Specifically Target Biofilmmentioning

confidence: 99%

Biofilm-Related Infections: Bridging the Gap between Clinical Management and Fundamental Aspects of Recalcitrance toward Antibiotics

Lebeaux

Ghigo

Beloin

2014

Microbiol Mol Biol Rev

1,012

862

View full text Add to dashboard Cite

show abstract

“…According to the study researchers, use of these doses of oritavancin for S. aureus, although effective against pneumococci, warrants further analysis. A mild to moderate reduction in the potency of oritavancin by surfactant has been reported although the effect is much lower than that with daptomycin [40].…”

Section: Pharmacokineticsmentioning

confidence: 98%

Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains

Bouza

Burillo

2010

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Oritavancin is a lipoglycopeptide antibiotic under investigation for the treatment of serious infections caused by Gram-positive bacteria. Oritavancin has demonstrated rapid dose-dependent bactericidal activity towards vancomycin-susceptible and -resistant enterococci, meticillin-susceptible and -resistant Staphylococcus aureus, vancomycin-intermediate S. aureus (VISA), heteroresistant VISA (hVISA), vancomycin-resistant S. aureus (VRSA) and small-colony variants of S. aureus. It is also active against Clostridium difficile. Upon intravenous administration, oritavancin displays a three-compartment pharmacokinetic model, dose proportionality, a distribution volume of ca. 110 L, a terminal elimination half-life in excess of 2 weeks and it is not metabolised. Its pharmacodynamic properties make it an ideal antibiotic for a once-daily or even single-dose regimen. Oritavancin is currently under review by the US Food and Drug Administration. So far, oritavancin has demonstrated efficacy in two pivotal Phase III trials conducted in patients with complicated skin and skin-structure infections in which oritavancin was compared with vancomycin plus cefalexin. In both trials, the primary endpoint (clinical cure in clinically evaluable patients at first follow-up with a 10% non-inferiority margin) was met, with the advantages of shorter duration of therapy and fewer adverse events. Further results indicating its activity against bacteria growing in biofilms as well as stationary-phase bacteria open the way for its use to treat prosthetic device infections, which is to be investigated in upcoming trials.

show abstract

“…El agente causal más frecuente es el Staphylococcus aureus en el 75% de los casos (7,8); hasta hace una década el 15% era meticilino-resistente y el 85% era sensible, pero en esta última década en algunas series hasta 40% son resistentes a la meticilina (5,9). Luego está el Staphylococcus epidermidis, principalmente cuando hay antecedente de instrumentación; Escherichia coli, si existe el antecedente de una infección urinaria; Pseudomona aeruginosa en pacientes que usan drogas endovenosas.…”

Section: Dr Eduardo Matosunclassified

Conversatorio clínico patológico en el Hospital Nacional Arzobispo Loayza_2010-02

et al. 2011

View full text Add to dashboard Cite

New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus

Cited by 18 publications

References 302 publications

Biofilm-Related Infections: Bridging the Gap between Clinical Management and Fundamental Aspects of Recalcitrance toward Antibiotics

Biofilm-Related Infections: Bridging the Gap between Clinical Management and Fundamental Aspects of Recalcitrance toward Antibiotics

Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains

Conversatorio clínico patológico en el Hospital Nacional Arzobispo Loayza_2010-02

Contact Info

Product

Resources

About